On Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on and recommended a marketing authorization for Mylan and Biocon’s Semglee, an insulin glargine follow-on that will be available in the European Union as a solution for injection for patients with diabetes.
On Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on and recommended a marketing authorization for Mylan and Biocon’s Semglee, an insulin glargine follow-on that will be available in the European Union as a solution for injection for patients with diabetes.
The drug will now be referred to the European Commission, which is expected to grant a final marketing authorization for the product. If approved, Semglee, referenced on Lantus, will compete with other biosimilars of insulin glargine, including Lusduna, approved for marketing in the EU in January 2017, and Abasaglar, approved in September 2014.
The positive CHMP opinion follows the June 2017 release of data from the INSTRIDE studies at the American Diabetes Association Scientific Sessions, which confirmed the efficacy, safety, and immunogenicity of Semglee in comparison to Lantus in patients with type 1 and type 2 diabetes. Shortly after the INSTRIDE data were reported, Biocon received a certificate of compliance from the European Union for its manufacturing facility in Malaysia, where it plans to produce the insulin product.
In the US marketplace, where Mylan and Biocon also hope to gain approval for the drug, Sanofi, maker of the reference product, has sued Mylan over the biosimilar. Sanofi’s suit alleges that Mylan infringed on 18 patents for the drug after Mylan filed a New Drug Application for the product with the FDA (in the United States, insulins are regulated as drugs and not as biologics; hence, drug makers must submit NDAs rather than biologics license applications for follow-ons of originator products). According to Sanofi, the Mylan NDA included a challenge to all of Sanofi’s patents listed for Lantus in the FDA’s orange book.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.